Who makes NRX 195183 Soft Gelatin Capsule?

NRX 195183 Soft Gelatin Capsule is developed by NuRx Pharmaceuticals, Inc..

What development phase is NRX 195183 Soft Gelatin Capsule in?

NRX 195183 Soft Gelatin Capsule is in Phase 2.

Last reviewed 2026-04-19 · How we verify

NRX 195183 Soft Gelatin Capsule

NuRx Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	NRX 195183 Soft Gelatin Capsule
Sponsor	NuRx Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NRX 195183 Soft Gelatin Capsule CI brief — competitive landscape report
NRX 195183 Soft Gelatin Capsule updates RSS · CI watch RSS
NuRx Pharmaceuticals, Inc. portfolio CI